Related references
Note: Only part of the references are listed.Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt et al.
LANCET (2017)
Dupilumab Improves General Health-Related Quality-of-Life in Patients with Moderate-to-Severe Atopic Dermatitis: Pooled Results from Two Randomized, Controlled Phase 3 Clinical Trials
Eric L. Simpson
DERMATOLOGY AND THERAPY (2017)
Targeting key proximal drivers of type 2 inflammation in disease
Namita A. Gandhi et al.
NATURE REVIEWS DRUG DISCOVERY (2016)
Burden of Sleep and Fatigue in US Adults With Atopic Dermatitis
Sherry H. Yu et al.
DERMATITIS (2016)
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis A Randomized Clinical Trial
Claus Bachert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD)
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: Many options, no standards
Masaki Futamura et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2016)
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
Diamant Thaci et al.
LANCET (2016)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
E. L. Simpson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Guidelines of care for the management of atopic dermatitis
Robert Sidbury et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Psychiatric Disorders and Sleep Issues
Eliza L. Sutton
MEDICAL CLINICS OF NORTH AMERICA (2014)
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Thymic Stromal Lymphopoietin Variation, Filaggrin Loss of Function, and the Persistence of Atopic Dermatitis
David J. Margolis et al.
JAMA DERMATOLOGY (2014)
Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis
Mayte Suarez-Farinas et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Climatic Factors Are Associated with Childhood Eczema Prevalence in the United States
Jonathan I. Silverberg et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2013)
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Sally Wenzel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Assessment of Pruritus Intensity: Prospective Study on Validity and Reliability of the Visual Analogue Scale, Numerical Rating Scale and Verbal Rating Scale in 471 Patients with Chronic Pruritus
Ngoc Quan Phan et al.
ACTA DERMATO-VENEREOLOGICA (2012)
EASI, (objective) SCORAD and POEM for atopic eczema: responsiveness and minimal clinically important difference
M. E. Schram et al.
ALLERGY (2012)
Progressive activation of TH2/TH22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis
Julia K. Gittler et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
Health-related quality of life in patients with atopic dermatitis
Natasa Maksimovic et al.
JOURNAL OF DERMATOLOGY (2012)
MECHANISMS OF DISEASE Filaggrin Mutations Associated with Skin and Allergic Diseases
Alan D. Irvine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
The 5-D itch scale: a new measure of pruritus
S. Elman et al.
BRITISH JOURNAL OF DERMATOLOGY (2010)
Epidermal Barrier Dysfunction in Atopic Dermatitis
Michael J. Cork et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
Disease severity, scratching, and sleep quality in patients with atopic dermatitis
Bruce G. Bender et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2008)
IL-4 receptor α is an important modulator of IL-4 and IL-13 receptor binding:: Implications for the development of therapeutic targets
Allison-Lynn Andrews et al.
JOURNAL OF IMMUNOLOGY (2006)
Interpreting scores on the Quality of Life Index for Atopic Dermatitis (QoLIAD)
DM Meads et al.
VALUE IN HEALTH (2005)
A new instrument for assessing quality of life in atopic dermatitis: international development of the Quality of Life Index for Atopic Dermatitis (QoLIAD)
D Whalley et al.
BRITISH JOURNAL OF DERMATOLOGY (2004)
Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: An objective life quality measure
BG Bender et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2003)
The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis
JM Hanifin et al.
EXPERIMENTAL DERMATOLOGY (2001)